Sutro Biopharma (STRO) Q3 2026 earnings summary

Executive summary

• STRO-006 began Phase 1 dosing in October 2026; STRO-004 dose optimization continues, with an update and expansion cohorts planned for H1 2027; STRO-227 Phase 1 is targeted for early 2027.

• Nine-month net loss narrowed to $108.5M from $144.3M, while revenue fell to $33.5M from $90.8M, largely reflecting prior-year Ipsen revenue recognition.

• Cash, cash equivalents and marketable securities totaled $142.2M at September 30, 2026; runway is expected into H1 2028 under the current operating plan, though further financing will be needed.

Financial highlights

• Q3 revenue was $9.1M vs. $9.7M; operating expenses were $31.1M vs. $58.2M, operating loss was $22.0M vs. $48.5M, and net loss was $31.5M vs. $56.9M.

• Q3 basic and diluted loss per share was $1.90 vs. $6.66; expenses included $23.5M R&D, $7.5M G&A and $0.02M restructuring costs.

• Nine-month revenue was $33.5M vs. $90.8M; operating expenses were $115.0M vs. $211.2M, and operating loss was $81.5M vs. $120.3M.

• Nine-month basic and diluted loss per share was $7.03 vs. $17.03; restructuring costs were $0.3M vs. $49.0M, following completion of most restructuring activity in Q1 2026.

Outlook and guidance

• STRO-004 Phase 1 update and expansion cohorts in select indications are expected in H1 2027; dose optimization continues in selected backfill cohorts.

• Initial STRO-006 clinical update is expected in H2 2027; STRO-227 Phase 1 initiation is targeted for early 2027.

• Existing unrestricted cash, cash equivalents and marketable securities are expected to support operations for at least 12 months after filing; additional financing will be required.

• No significant future restructuring expenses are expected; final luvelta-related costs depend on CRO/CMO commitments and clinical-trial wind-down.